SCHEMBL7124170

SCHEMBL7124170

Nc1ccc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.44
MMP7 P09237 1/20 0.44
MMP9 P14780 1/20 0.44
MMP13 P45452 1/20 0.44
ST14 Q9Y5Y6 5/20 0.43
PARP10 Q53GL7 1/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
IKZF3 Q9UKT9 1/20 0.41
EZH2 Q15910 1/20 0.39
USP30 Q70CQ3 2/20 0.38
F2 P00734 4/20 0.37
PRSS1 P07477 3/20 0.37
PRSS2 P07478 3/20 0.37
PRSS3 P35030 3/20 0.37
PLG P00747 2/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7121935 0.90 PARP10 (0.46) MMP2MMP7MMP9MMP13ST14
SCHEMBL7124896 0.89 MMP2 (0.57) MMP2MMP7MMP9MMP13EZH2
SCHEMBL7120658 0.89 MMP2 (0.45) MMP2MMP7MMP9MMP13ST14
SCHEMBL7124023 0.89 MMP2 (0.45) MMP2MMP7MMP9MMP13ST14
SCHEMBL7121780 0.88 SLC6A3 (0.46) MMP2MMP7MMP9MMP13EZH2
SCHEMBL7124966 0.88 SLC6A4 (0.46) MMP2MMP7MMP9MMP13TSHR
SCHEMBL7127599 0.88 NAAA (0.49) MMP2MMP7MMP9MMP13PARP10
SCHEMBL7116944 0.88 HPGD (0.46) MMP2MMP7MMP9MMP13EZH2
Hydrochloric Acid SCHEMBL7124074 0.87 SLC6A3 (0.45) MMP2MMP7MMP9MMP13EZH2
SCHEMBL7117924 0.86 CA1 (0.43) MMP2MMP7MMP9MMP13HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 MMP2 3731/4885MMP7 2061/4885MMP9 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.